Indeed, tumor‐suppressive properties of AIM2 have been identified in hepatocellular carcinoma,14 renal carcinoma,15 breast cancer,16 colon cancer,13 HPV‐infected cervical carcinoma,17 and prostate cancer.18 Here, AIM2 is linked to prostate carcinoma.